Log In
Print
BCIQ
Print
Print this Print this
 

JR-032

  Manage Alerts
Collapse Summary General Information
Company JCR Pharmaceuticals Co. Ltd.
DescriptionRecombinant iduronate-2-sulfatase rDNA origin manafactured using serum-free culture technology
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation
Partner GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today